Atypical antipsychotic that displays combined serotonin and dopamine receptor antagonism. Displays high affinity at 5-HT2A receptors with a 5-HT2A/D2 affinity ratio greater than any other clinically available atypical antipsychotics (pKi values are 9.38, 8.88, 8.69, 8.47, 8.32, 8.14, 7.98, 7.49, 7.33 and 6.28 for 5-HT2A, 5-HT2C, 5-HT1D, 5-HT1A, D2, D3, α1, D4, H1 and D1 receptors respectively).
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 449.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||22.25 mL||111.26 mL||222.52 mL|
|0.5 mM||4.45 mL||22.25 mL||44.5 mL|
|1 mM||2.23 mL||11.13 mL||22.25 mL|
|5 mM||0.45 mL||2.23 mL||4.45 mL|
References are publications that support the biological activity of the product.
Seeger et al (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J.Pharmacol.Exp.Ther. 275 101 PMID: 7562537
Schmidt et al (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur.J.Pharmacol. 425 197 PMID: 11513838
Fell et al (2005) Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav.Brain Res. 160 338 PMID: 15863230
If you know of a relevant reference for Ziprasidone hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Ziprasidone hydrochloride, Ziprasidone hydrochloride supplier, 5-HT2A/D2, antagonists, atypical, antipsychotic, Serotonin, 5-HT2A, Receptors, Dopamine, dopaminergic, CP88059, Pfizer, CP, 88059, D2, 3085, Tocris Bioscience
3 Citations for Ziprasidone hydrochloride
Citations are publications that use Tocris products. Selected citations for Ziprasidone hydrochloride include:
Canfrán-Duque et al (2013) Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 54 310 PMID: 23175778
Canfrán-Duque et al (2015) Curcumin Mitigates the Intracellular Lipid Deposit Induced by Antipsychotics In Vitro. Mediators Inflamm 10 e0141829 PMID: 26517556
Schulz et al (2012) First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol 167 1480 PMID: 22817643
Do you know of a great paper that uses Ziprasidone hydrochloride from Tocris? Please let us know.
Reviews for Ziprasidone hydrochloride
There are currently no reviews for this product. Be the first to review Ziprasidone hydrochloride and earn rewards!
Have you used Ziprasidone hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.